Digital Health Global
MARCH 2, 2023
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. We look for similar customer-oriented ethos and patient-centric mindsets in our partnerships,” said Kim Kushner, Chief Business Officer, SSI Strategy. Learn more at koneksahealth.com.
Digital Health Global
OCTOBER 11, 2023
The acquisition immediately expands EVERSANA’s European operations and worldwide capabilities to help pharmaceutical, medical device, and emerging biotech companies globally launch products, expand market access, or solve unique geographic and market-specific challenges. Financial details of the acquisition are not being disclosed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Digital Health Global
MARCH 27, 2024
“In only seven years, Health+Commerce has built a highly respected organization providing strategic programs that reach clinician, investor and consumer audiences in the multibillion-dollar medtech, biotech and digital health sectors. We look forward to supporting the agency as it continues on its growth trajectory.”
Healthcare IT Today
JANUARY 23, 2024
Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients.
Lloyd Price
MAY 5, 2024
Mergers, Acquisitions, Growth and Strategy for Healthcare Technology companies HealthTech M&A - Buy Side, Sell Side, Growth & Strategy services for companies in Europe, Middle East and Africa. link] Healthcare Technology Buy Side, Sell Side, Growth & Strategy services for Founders, Owners and Investors.
Digital Health Global
FEBRUARY 5, 2024
At Solas, we invest in game-changing healthcare innovation and strong leadership teams committed to creating meaningful patient impact,” said Dr. David Adair, Managing Director of Solas BioVentures. This strategy has been validated through a number of companies in both Fund I and II and the Colucid Pharmaceuticals exit.
Digital Health Global
AUGUST 2, 2023
Colin’s track record with global biopharma and biotech partners is extensive and admirable,” added Chris Garabedian, a VivoSense Board Member. “He Colin has demonstrated strong leadership to his teams and customers alike.” Contacts Rob Wilson – Vice President of Marketing Strategy rob.wilson@vivosense.com Tel: +1 858-876-8486
Expert insights. Personalized for you.
88 
Let's personalize your content